Semaglutide vs Endoscopic Sleeve Gastroplasty for Weight Loss

Abstract

This study suggests that ESG is cost saving compared with semaglutide in the treatment of class II obesity. On price threshold analyses, a 3-fold decrease in the price of semaglutide is needed to achieve nondominance.